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OBJECTIVE — To evaluate the inﬂuence of lipid and glucose metabolism in the metabolic
syndrome on aortic pulse wave velocity (PWV) and left ventricular (LV) diastolic function using
magnetic resonance imaging (MRI).
RESEARCH DESIGN AND METHODS — Aortic PWV and LV diastolic function were
assessed using MRI in 16 subjects with the metabolic syndrome and 16 subjects without the
metabolicsyndromematchedforage,waistcircumference,andbloodpressure.Thegroupswere
compared using the unpaired t test or Mann-Whitney U test, and linear regression analysis was
applied.
RESULTS — Aortic PWV was increased and LV diastolic function was decreased in subjects
withcomparedwiththosewithoutthemetabolicsyndrome.HDLcholesterolwasindependently
associatedwithaorticPWV(R0.470,P0.01)andLVdiastolicfunction(R0.421,P
0.02).
CONCLUSIONS — IncreasedaorticPWVanddecreasedLVdiastolicfunctionisobservedin
subjects with the metabolic syndrome, regardless of blood pressure. Moreover, HDL cholesterol
is independently associated with aortic PWV and LV diastolic function.
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P
revious studies have demonstrated
thatthemetabolicsyndromeisasso-
ciated with increased arterial stiff-
ness and left ventricular (LV) dysfunction
(1,2). However, the exact mechanism re-
sponsible for these alterations is unclear
and has not yet been studied with mag-
netic resonance imaging (MRI). We hy-
pothesized that abnormalities in lipid or
glucose metabolism contribute to the ad-
verse cardiovascular changes in the meta-
bolic syndrome. Accordingly, the study
purposewastocompareaorticpulsewave
velocity (PWV) and LV function using
MRIinsubjectswithandwithoutthemet-
abolic syndrome and to evaluate the rela-
tion between lipid and glucose
metabolism and cardiovascular function.
RESEARCH DESIGN AND
METHODS— MRI examination was
performed in 16 Caucasian male subjects
with recently diagnosed, untreated meta-
bolic syndrome (per International Diabe-
tes Federation criteria) and 16 Caucasian
male subjects without the metabolic syn-
drome (sample size calculation: 80%
power,  0.05) (3) matched for age, waist
circumference, and blood pressure. Only
male subjects were included to avoid po-
tential confounding effects of sex on MRI
results and blood values. No participants
showed evidence of cardiovascular dis-
ease,diabetes,orbeingasmoker.Labora-
tory measurements (triglycerides, HDL
cholesterol, total cholesterol, fasting
blood glucose, glycated hemoglobin, in-
sulin,andhigh-sensitivityC-reactivepro-
tein[hs-CRP])wereperformedjustbefore
the MRI. Approval from the local ethics
committee and informed consent were
obtained.
MRI was performed on a 1.5-T scan-
ner (Philips) using a ﬁve-element cardiac
coil, and heart rate was registered. Aortic
PWV was assessed with a technique with
good reproducibility, using a retrospec-
tively electrocardiogram-gated fast ﬁeld-
echo sequence with velocity encoding
(temporal resolution 6–10 ms), acquired
at two predeﬁned levels (thoracic ascend-
ing and abdominal aorta) (4,5). For eval-
uation of LV systolic function, the heart
was imaged in short-axis view using an
electrocardiogram-triggered balanced
turbo ﬁeld-echo sequence (4). A three-
dimensional three-directional velocity-
encoded (3D-VE) MRI technique was
usedforassessmentoftransmitralﬂowfor
evaluation of LV diastolic function (6).
Data were analyzed with MASS/
FLOW (Medis, Leiden, Netherlands).
PWV was calculated as the aortic path
length between two imaging sites divided
by the transit time between arrival of the
pulse wave at these sites (4). LV end-
systolic volume, end-diastolic volume,
ejection fraction, and end-diastolic mass
were assessed.
The transmitral ﬂow was recon-
structed from the 3D-VE MRI acquisi-
tions (6). The following variables of
diastolic function were derived: peak ﬁll-
ingrate(PFR)oftheearlyﬁllingwave(E),
E deceleration peak and mean, E deceler-
ation time, PFR of the atrial ﬁlling wave
(A), and E/A peak ﬂow ratio.
Data are expressed as the mean  SD
or median (interquartile range). Differ-
ences between groups were analyzed us-
ing the unpaired t test or Mann-Whitney
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normally distributed variables, univariate
linear regression analysis was performed
in the pooled dataset to analyze the asso-
ciation between clinical and MRI vari-
ables (Pearson correlation coefﬁcients [R]
and P values). Variables with a univariate
linear regression with P  0.10 were in-
cluded in a stepwise multiple linear re-
gression analysis. P  0.05 was
considered statistically signiﬁcant.
RESULTS— Table 1 shows clinical
characteristicsandMRIresults.Heartrate
was similar in the two groups during MRI
examination.
PWV was signiﬁcantly higher in sub-
jects with than in those without the met-
abolic syndrome. Univariate linear
regressionanalysisshowedthatHDLcho-
lesterol was signiﬁcantly associated with
PWV (R  0.470, P  0.01). This asso-
ciation was more pronounced in the aor-
ticarchthaninthemoredistalaorta(data
not shown). A trend toward a correlation
between hs-CRP and PWV (R  0.326,
P0.1)wasalsoobserved.Nosigniﬁcant
association was observed between age,
waist circumference, blood pressure, re-
maining laboratory measurements, and
PWV. Multiple regression analysis in-
cluding HDL cholesterol and hs-CRP
showed that only HDL cholesterol was
signiﬁcantly associated with PWV.
Signiﬁcant differences in E decelera-
tion peak and mean between the two
groups were observed, indicating de-
creased diastolic function (impaired re-
laxation) in subjects with the metabolic
syndrome. Univariate linear regression
showed that HDL cholesterol was signiﬁ-
cantly associated with E deceleration
mean and E deceleration time (R 
0.421, P  0.021, and R  0.380,
P  0.038, respectively). No signiﬁcant
association was observed between age,
waist circumference, blood pressure,
other laboratory measurements, and dia-
stolic function. Similar correlations were
detected between total cholesterol–to–
HDL cholesterol ratio and cardiovascular
function (data not shown).
CONCLUSIONS — To our knowl-
edge,thisistheﬁrststudytoevaluateaor-
tic stiffness and LV diastolic function in
one examination using MRI in the meta-
bolic syndrome. The results demonstrate
increased PWV and impaired LV diastolic
function in subjects with the metabolic
syndrome, regardless of blood pressure.
Moreover, HDL cholesterol was indepen-
dently associated with PWV and LV dia-
stolic function, suggesting adverse
cardiovascular changes in the presence of
low HDL cholesterol levels.
The present ﬁndings of increased ar-
terial stiffness and decreased LV diastolic
functioninthemetabolicsyndromearein
line with previous studies using tech-
niquesotherthanMRI(1,2).Importantly,
in our study, these unfavorable changes
could not be ascribed to age, waist cir-
cumference, or blood pressure. This ob-
servational study does not allow for
revelation of the exact underlying mech-
anism of the observed alterations; how-
ever, the signiﬁcant association between
HDL cholesterol and PWV and diastolic
function suggests that lipid metabolism
might play a role. The anti-atherogenic
properties of HDL cholesterol (including
maintenance of endothelial function [ni-
tric oxide], reverse cholesterol transport,
and anti-inﬂammatory properties) might
protectagainstarterialstiffening.Further-
more, insulin resistance and low-grade
inﬂammation may contribute to arterial
stiffening (7). In contrast to patients with
diabetes,formationofadvancedglycation
end products is not likely to play a major
role in arterial stiffening in these normo-
glycemic subjects. Increased arterial stiff-
ness itself can hamper diastolic function
through early reﬂection of the pulse wave
leading to increased LV afterload and de-
creased myocardial perfusion. Other pos-
sible factors contributing to diastolic
dysfunction include macrovascular (cor-
onary) and microvascular endothelial
dysfunction and insulin resistance (8).
Limitationsofthisstudyincludethesmall
samplesizeandtheinclusionofonlymale
subjects; our results therefore require
Table 1—Clinical characteristics and MRI results of the study population
Subjects without the
metabolic syndrome
Subjects with the
metabolic syndrome P
Clinical characteristics
Age (years) 60  56 0  5 0.8
Waist circumference (cm) 106  9 111  11 0.2
Systolic blood pressure (mmHg) 142  17 145  17 0.6
Diastolic blood pressure (mmHg) 89  98 8  8 0.9
Triglycerides (mmol/l) 1.3  0.7 1.9  0.6 0.01
HDL cholesterol (mmol/l) 1.8  0.3 1.2  0.2 0.001
Total cholesterol (mmol/l) 5.7  0.9 5.9  1.0 0.6
Total-to-HDL cholesterol ratio 3.3  0.7 5.1  0.7 0.001
Fasting plasma glucose (mmol/l)* 4.7 (1.0) 5.0 (1.3) 0.029
A1C (%) 5.0  0.4 5.2  0.5 0.1
Insulin (mU/l)* 6.5 (4.5) 12.0 (11.5) 0.014
HOMA-IR (mmol/l  mU/l)* 1.2 (0.83) 2.9 (3.0) 0.010
hs-CRP (mmol/l)* 1.1 (0.98) 2.7 (2.5) 0.001
Aortic stiffness
Aortic PWV (m/s) 6.0  1.0 7.4  2.0 0.018
Cardiac volumes and function
LVEDV-I (ml/m
2) 82  27 84  12 0.7
LVESV-I (ml/m
2) 33  12 35  6 0.7
LVEDM-I (g/m
2) 56  17 58  9 0.7
LV ejection fraction (%) 59  55 9  4 0.7
E peak ﬁlling rate (ml/s) 503  100 456  98 0.2
E deceleration peak (ml/s
2)  10
3 4.6  1.3 3.7  1.0 0.044
E deceleration mean (ml/s
2)  10
3 3.0  0.9 2.4  0.7 0.032
E deceleration time (ms) 155  27 180  36 0.043
A peak ﬁlling rate (ml/s) 448  76 463  61 0.5
E/A peak ratio 1.1  0.2 1.0  0.2 0.1
Data are means  SD or median interquartile range. Insulin resistance was calculated according to the
homeostatic model assessment (HOMA-IR) method deﬁned as: HOMA-IR(mmol/l  mU/l)  fasting glu-
cose(mmol/l)fastinginsulin(mU/l)/22.5.*Variablesnon-normallydistributedandthereforeexpressedas
median (interquartile range); Mann-Whitney U test was used to compare the two groups. The remaining
variables were normally distributed and therefore expressed as means  SD; unpaired t test was used to
compare the two groups. Diastolic function could not be calculated in two subjects with the metabolic
syndrome due to technical problems. A, atrial ﬁlling wave; E, early ﬁlling wave; LVEDM, left ventricular
end-diastolic mass; LVEDV, left ventricular end-diastolic volume; LVESV, left ventricular end-systolic vol-
ume.
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